Dasatinib, a second-generation drug developed for CML (chronic myeloid leukemia) that also acts on cKIT, has better CNS penetration and perhaps more toxicity than imatinib. Here, KIT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.